Nalaganje...

SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study

INTRODUCTON: Remogliflozin is new SGLT2i recently approved in India, but more economical than the previously available SGLT2i. It is prudent to evaluate its effectiveness & tolerability in comparison to other SGLT2i in real world setting. METHODS: In this observational retrospective study, medic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Bhattacharyya, Supratik, Katare, Sagar
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208915/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.2146
Oznake: Označite
Brez oznak, prvi označite!